SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 9, 2004
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Commission File Number)|| |
|1600 Faraday Avenue, Carlsbad, CA||92008|
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code (760) 603-7200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|x||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Section 8 Other Events
Item 8.01 Other Events.
On December 9, 2004, Invitrogen Corporation (the Company) issued a press release announcing it has completed its exchange offer with respect to the Companys 2.0% Convertible Senior Notes due 2023 and the Companys 1.5% Convertible Senior Notes due 2024. The press release is attached hereto as Exhibit 99.1.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
|99.1||December 9, 2004 Press Release by Invitrogen Corporation|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date December 9, 2004|
/s/ JOHN A. COTTINGHAM
|John A. Cottingham|
|Senior Vice President, General Counsel and Secretary|